Literature DB >> 12601534

[Neoadjuvant chemotherapy of primary hepatic non-Hodgkin's lymphoma].

Sebastian Eidt1, Manfred Nebeling, Christoph Pohl, Michel Siedek.   

Abstract

BACKGROUND: Since primary malignant lymphomas of the liver represent a rare entity, no commonly accepted therapeutic strategy has been developed so far. CASE STUDY: We report the case of a diffuse large-cell B-cell lymphoma of the liver in a 48-year-old female patient. The tumor presented as a solitary mass measuring 12.5 cm in maximum diameter. After neoadjuvant chemotherapy, the lymphoma was completely resected (R0). A massive therapy-induced tumor regression was found histologically. No involvement of regional lymph nodes or other organs was detected during staging procedures (stage I EA). After six courses of adjuvant chemotherapy, the patient has been alive and well for more than 5 years and shows no evidence of tumor relapse.
CONCLUSION: This case documents the effect of systemic chemotherapy on lymphoma cells. In many centers systemic chemotherapy is used as the only therapeutic regimen. Neoadjuvant chemotherapy might, however, represent an important addition to the therapeutic strategies concerning unilocular primary hepatic lymphomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601534     DOI: 10.1007/s00063-003-1232-6

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  2 in total

1.  Primary hepatic lymphoma: features of a puzzling disease.

Authors:  Magalí Chahdi Beltrame; Martín De Santibañes; Victoria Ardiles; Oscar Mazza; Juan Pekolj; Eduardo De Santibañes; Rodrigo Sánchez Clariá
Journal:  J Gastrointest Cancer       Date:  2015-06

2.  A primary hepatic lymphoma treated with liver resection and chemotherapy.

Authors:  Konstantinos Bouliaris; Grigorios Christodoulidis; Georgios Koukoulis; Ioannis Mamaloudis; Maria Ioannou; Eleni Bouronikou; Maria Palassopoulou; Konstantinos Tepetes
Journal:  Case Rep Surg       Date:  2014-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.